{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:51:14Z","timestamp":1790873474931,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.neurol.2009.07.017","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T04:17:01Z","timestamp":1254889021000},"page":"168-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hypoth\u00e8ses pharmacologiques et prise en charge th\u00e9rapeutique des troubles de la marche de la maladie de Parkinson"],"prefix":"10.1016","volume":"166","author":[{"given":"D.","family":"Devos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Defebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2009.07.017_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archneur.1992.00530290152026","article-title":"Dopamine agonist treatment of fluctuating Parkinsonism. D-2 (controlled release-release MK-458) versus combined D-1 and D-2 (pergolide)","volume":"49","author":"Ahlskog","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002826-200601000-00005","article-title":"Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: A pilot study","volume":"29","author":"Auriel","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2009.07.017_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.33588\/rn.4001.2004062","article-title":"The effects of lesions in the compact part of the substantia nigra on glutamate and GABA release in the pedunculopontine nucleus","volume":"40","author":"Blanco-Lezcano","year":"2005","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2009.07.017_bib5","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/mds.21065","article-title":"Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered","volume":"21","author":"Braak","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.21541","article-title":"A critical evaluation of the Braak staging scheme for Parkinson's disease","volume":"64","author":"Burke","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00002826-200107000-00003","article-title":"Methylphenidate increases the motor effects of l-DOPA in Parkinson's disease: a pilot study","volume":"24","author":"Camicioli","year":"2001","journal-title":"Clin Neuroparmacol"},{"key":"10.1016\/j.neurol.2009.07.017_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02246054","article-title":"Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms","volume":"119","author":"Carroll","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurol.2009.07.017_bib9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-3565(24)38022-X","article-title":"Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway","volume":"288","author":"Chopin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2009.07.017_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/01.WNL.0000161841.41885.80","article-title":"Short-term paroxetine treatment does not alter the motor response to levodopa in PD","volume":"64","author":"Chung","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2009.07.017_bib11","first-page":"CD003468","article-title":"Amantadine in Parkinson's disease","volume":"1","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2009.07.017_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp.2006.100016","article-title":"Improvement of gait by chronic high doses of methylphenidate in advanced parkinsonian patients under subthalamic stimulation","volume":"78","author":"Devos","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2009.07.017_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.22450","article-title":"Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease","volume":"24","author":"Devos","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib15","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00415-006-0175-2","article-title":"Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease","volume":"253","author":"Dujardin","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib16","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2009.07.017_bib17","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2009.07.017_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V","article-title":"Serotonin 5-HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys","volume":"39","author":"Frechilla","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.neurol.2009.07.017_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.17302","article-title":"Selective serotonin-reuptake inhibitor-induced movement disorders","volume":"32","author":"Gerber","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2009.07.017_bib20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1212\/WNL.56.12.1712","article-title":"Freezing of gait in PD: prospective assessment in the DATATOP cohort","volume":"56","author":"Giladi","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2009.07.017_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s007020170096","article-title":"Freezing of gait in patients with advanced Parkinson's disease","volume":"108","author":"Giladi","year":"2001","journal-title":"J Neural Transm"},{"issue":"Suppl. 9","key":"10.1016\/j.neurol.2009.07.017_bib22","first-page":"S191","article-title":"Rasagiline can improve freezing of gait in advanced Parkinson's disease: a prospective randomized, double blind placebo and entacapone controlled study","volume":"19","author":"Giladi","year":"2004","journal-title":"Mov Disord"},{"issue":"Suppl. 2","key":"10.1016\/j.neurol.2009.07.017_bib23","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1002\/mds.21914","article-title":"Medical treatment of freezing of gait","volume":"23","author":"Giladi","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib24","first-page":"277","article-title":"Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease","volume":"29","author":"Henderson","year":"1992","journal-title":"Clin Exp Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF01277663","article-title":"Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders","volume":"104","author":"Iacono","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2009.07.017_bib26","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.20968","article-title":"Association between amantadine and the onset of dementia in Parkinson's disease","volume":"21","author":"Inzelberg","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.neurol.2009.07.017_bib28","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.parkreldis.2006.05.018","article-title":"Drug intervention for freezing of gait resistant to dopaminergic therapy: A pilot study","volume":"12","author":"Kondo","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0149-7634(96)00043-7","article-title":"Dopamine\/glutamate interactions in Parkinson's disease","volume":"21","author":"Lange","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.neurol.2009.07.017_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.31.8.961","article-title":"Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa","volume":"31","author":"Lieberman","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2009.07.017_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biopsych.2004.10.011","article-title":"The dopamine transporter and attention-deficit\/hyperactivity disorder","volume":"57","author":"Madras","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurol.2009.07.017_bib32","unstructured":"Maertens de Noordhout A, Pepin JL, Delwaide PJ. Open study of tinazidine in the treatment of freezing gait. 11th International Symposium on Parkinson's disease; 1994; Rome."},{"key":"10.1016\/j.neurol.2009.07.017_bib33","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study","volume":"22","author":"Merello","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2009.07.017_bib34","first-page":"467","article-title":"A long-term clinical effect of selegiline hydrochloride on Parkinson's disease","volume":"48","author":"Mizuno","year":"1996","journal-title":"No To Shinkei"},{"key":"10.1016\/j.neurol.2009.07.017_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00702-008-0099-3","article-title":"Externally provoked freezing of gait in open runways in advanced Parkinson's disease results from motor and mental collapse","volume":"115","author":"Moreau","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2009.07.017_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.20089","article-title":"The dopamine transporter: importance in Parkinson's disease","volume":"55","author":"Nutt","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib37","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","article-title":"A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease: rationale, design, and baseline characteristics","volume":"23","author":"Olanow","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib38","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/brain\/123.9.1767","article-title":"The pedunculopontine nucleus and Parkinson's disease","volume":"123","author":"Pahapill","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2009.07.017_bib39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib40","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2009.07.017_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.20321","article-title":"Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia","volume":"57","author":"Parkkinen","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-211-73574-9_17","article-title":"Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state","volume":"72","author":"Pollak","year":"2007","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.neurol.2009.07.017_bib43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02260076","article-title":"Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease","volume":"4","author":"Rabey","year":"1992","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.neurol.2009.07.017_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3940(00)01244-1","article-title":"Age-related changes of neuronal counts in the human pedunculopontine nucleus","volume":"288","author":"Ransmayr","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2009.07.017_bib45","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2009.07.017_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2009.07.017_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0301-0082(95)00023-O","article-title":"The pedunculopontine nucleus \u2013 auditory input, arousal and pathophysiology","volume":"47","author":"Reese","year":"1995","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neurol.2009.07.017_bib48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.102.045005","article-title":"Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits","volume":"304","author":"Sandoval","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2009.07.017_bib49","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/BF01294722","article-title":"Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study","volume":"104","author":"Sarre","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2009.07.017_bib50","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2009.07.017_bib51","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1055\/s-2008-1069311","article-title":"Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study","volume":"109","author":"Schneider","year":"1984","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.neurol.2009.07.017_bib52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol anti-oxidative therapy of Parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2009.07.017_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01277594","article-title":"Memantine, amantadine, and L-deprenyl potentiate the action of l-DOPA in monoamine-depleted rats","volume":"98","author":"Skuza","year":"1994","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.neurol.2009.07.017_bib54","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/brain\/awl346","article-title":"Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease","volume":"130","author":"Stefani","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2009.07.017_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2003.08.001","article-title":"Effects of ibotenate pedunculopontine tegmental nucleus lesions on exploratory behaviour in the open field","volume":"151","author":"Steiniger","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.neurol.2009.07.017_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02260912","article-title":"The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients","volume":"5","author":"Tohgi","year":"1993","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.neurol.2009.07.017_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0304-3940(93)90111-W","article-title":"Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms","volume":"150","author":"Tohgi","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2009.07.017_bib58","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1523\/JNEUROSCI.1506-04.2004","article-title":"Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors","volume":"24","author":"Vizi","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2009.07.017_bib59","doi-asserted-by":"crossref","first-page":"RC121","DOI":"10.1523\/JNEUROSCI.21-02-j0001.2001","article-title":"Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain","volume":"21","author":"Volkow","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2009.07.017_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jns.2006.05.036","article-title":"How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies","volume":"248","author":"Winn","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2009.07.017_bib61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF02985055","article-title":"Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia","volume":"19","author":"Yener","year":"2005","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.neurol.2009.07.017_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378709003737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378709003737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:37:41Z","timestamp":1758519461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378709003737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0035378709003737"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2009.07.017","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoth\u00e8ses pharmacologiques et prise en charge th\u00e9rapeutique des troubles de la marche de la maladie de Parkinson","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2009.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}